189 related articles for article (PubMed ID: 27655641)
1. Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.
Chang JG; Chen CC; Wu YY; Che TF; Huang YS; Yeh KT; Shieh GS; Yang PC
Oncotarget; 2016 Nov; 7(45):73664-73680. PubMed ID: 27655641
[TBL] [Abstract][Full Text] [Related]
2. CSNK1E/CTNNB1 are synthetic lethal to TP53 in colorectal cancer and are markers for prognosis.
Tiong KL; Chang KC; Yeh KT; Liu TY; Wu JH; Hsieh PH; Lin SH; Lai WY; Hsu YC; Chen JY; Chang JG; Shieh GS
Neoplasia; 2014 May; 16(5):441-50. PubMed ID: 24947187
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of decreased GRK6 expression in lung adenocarcinoma.
Yao S; Zhong L; Liu J; Feng J; Bian T; Zhang Q; Chen J; Lv X; Chen J; Liu Y
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2541-2549. PubMed ID: 27601164
[TBL] [Abstract][Full Text] [Related]
4. The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition.
McAndrew EN; Lepage CC; McManus KJ
Oncotarget; 2016 Dec; 7(52):87417-87430. PubMed ID: 27902462
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Expression of Five Protein Combinations Revealed as Prognostic Markers in Asian Oral Cancer.
Wang HC; Chiang CJ; Liu TC; Wu CC; Chen YT; Chang JG; Shieh GS
Front Genet; 2021; 12():643461. PubMed ID: 33936170
[TBL] [Abstract][Full Text] [Related]
6. Genome-scale meta-analysis of DNA methylation during progression of lung adenocarcinoma.
Zhang QH; Dai XH; Dai ZM; Cai YN
Genet Mol Res; 2015 Aug; 14(3):9200-14. PubMed ID: 26345853
[TBL] [Abstract][Full Text] [Related]
7. The Overexpression of FEN1 and RAD54B May Act as Independent Prognostic Factors of Lung Adenocarcinoma.
Hwang JC; Sung WW; Tu HP; Hsieh KC; Yeh CM; Chen CJ; Tai HC; Hsu CT; Shieh GS; Chang JG; Yeh KT; Liu TC
PLoS One; 2015; 10(10):e0139435. PubMed ID: 26431531
[TBL] [Abstract][Full Text] [Related]
8. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
9. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract][Full Text] [Related]
10. A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.
Zhao Y; Varn FS; Cai G; Xiao F; Amos CI; Cheng C
Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):86-95. PubMed ID: 29141854
[No Abstract] [Full Text] [Related]
11. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
Ma X; Le Teuff G; Lacas B; Tsao MS; Graziano S; Pignon JP; Douillard JY; Le Chevalier T; Seymour L; Filipits M; Pirker R; Jänne PA; Shepherd FA; Brambilla E; Soria JC; Hainaut P;
J Thorac Oncol; 2016 Jun; 11(6):850-61. PubMed ID: 26899019
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
14. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.
Rakha E; Pajares MJ; Ilie M; Pio R; Echeveste J; Hughes E; Soomro I; Long E; Idoate MA; Wagner S; Lanchbury JS; Baldwin DR; Hofman P; Montuenga LM
Eur J Cancer; 2015 Sep; 51(14):1897-903. PubMed ID: 26235745
[TBL] [Abstract][Full Text] [Related]
15. An individualized gene expression signature for prediction of lung adenocarcinoma metastases.
Qi L; Li T; Shi G; Wang J; Li X; Zhang S; Chen L; Qin Y; Gu Y; Zhao W; Guo Z
Mol Oncol; 2017 Nov; 11(11):1630-1645. PubMed ID: 28922552
[TBL] [Abstract][Full Text] [Related]
16. Roles of highly expressed PAICS in lung adenocarcinoma.
Zhou S; Yan Y; Chen X; Wang X; Zeng S; Qian L; Wei J; Yang X; Zhou Y; Gong Z; Xu Z
Gene; 2019 Apr; 692():1-8. PubMed ID: 30641222
[TBL] [Abstract][Full Text] [Related]
17. Microtubule-Associated Protein 4 Is a Prognostic Factor and Promotes Tumor Progression in Lung Adenocarcinoma.
Xia X; He C; Wu A; Zhou J; Wu J
Dis Markers; 2018; 2018():8956072. PubMed ID: 29743960
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
[TBL] [Abstract][Full Text] [Related]
19. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
20. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.
Lai TC; Chow KC; Fang HY; Cho HC; Chen CY; Lin TY; Chiang IP; Ho SP
Oncol Rep; 2011 May; 25(5):1243-51. PubMed ID: 21327329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
